OPKO Health, Inc. (OPK) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

OPKO Health, Inc. (OPK) Healthcare & Pipeline Overview

OPKO Health, Inc. is a healthcare company engaged in diagnostics and pharmaceuticals, offering laboratory testing services through BioReference Laboratories and developing proprietary therapeutic proteins, including Rayaldee for kidney disease. The company operates internationally, with a focus on specialty APIs and pharmaceutical platforms.

What Is the Investment Thesis for OPK?

OPKO Health presents a mixed investment thesis. The company's diverse revenue streams from diagnostics and pharmaceuticals offer stability, but its negative profit margin of -36.6% raises concerns about profitability. The potential approval and commercialization of hGH-CTP, in partnership with Pfizer, could be a significant catalyst. The success of OPK88003 in Phase IIb trials for type 2 diabetes and obesity could drive future growth. However, the company's high beta of 1.49 indicates higher volatility compared to the market. Investors should closely monitor the progress of clinical trials, regulatory approvals, and the company's efforts to improve profitability.

Based on FMP financials and quantitative analysis

OPK Key Highlights

OPKO Health operates in both the diagnostics and pharmaceuticals sectors, providing diversification.

• BioReference Laboratories, a subsidiary, offers a wide range of diagnostic testing services.
• Rayaldee is a key pharmaceutical product targeting secondary hyperparathyroidism in chronic kidney disease patients.
• hGH-CTP, a once-weekly human growth hormone injection, completed Phase III clinical trials in partnership with Pfizer, Inc.
• The company has a market capitalization of $1.17B.

Who Are OPK's Competitors?

OPK is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are OPK's Key Strengths?

Diverse revenue streams from diagnostics and pharmaceuticals.

• Established presence in multiple geographic markets.
• Proprietary diagnostic technologies and pharmaceutical products.
• Partnerships with major pharmaceutical companies.

What Are OPK's Weaknesses?

Negative profit margin.

• High beta, indicating higher volatility.
• Dependence on regulatory approvals for new products.
• Competition from larger pharmaceutical and diagnostic companies.

What Could Drive OPK Stock Higher?

Potential regulatory approval and commercial launch of hGH-CTP in partnership with Pfizer.

• Progress of OPK88003 in Phase IIb clinical trials for the treatment of type 2 diabetes and obesity.
• Expansion of BioReference Laboratories' diagnostic testing services.
• Development and commercialization of new pharmaceutical products.

What Are the Key Risks for OPK?

Financial-distress signal — its Altman Z-Score of -0.29 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-16.8%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure to obtain regulatory approvals for new products.
• Competition from generic drugs and biosimilars.
• Negative profit margin and need to improve profitability.
• Dependence on key partnerships, such as the collaboration with Pfizer.
• Product liability claims and litigation.

What Are the Growth Opportunities for OPK?

• Expansion of Diagnostic Services: OPKO, through BioReference Laboratories, can expand its diagnostic testing services by offering new tests and increasing its market share in existing markets. The market for molecular diagnostics is projected to grow, driven by advancements in genomics and personalized medicine. This expansion could involve strategic acquisitions or partnerships with other diagnostic companies, increasing revenue and profitability.
• Commercialization of hGH-CTP: The successful commercialization of hGH-CTP, a once-weekly human growth hormone injection developed in partnership with Pfizer, represents a significant growth opportunity. Upon regulatory approval, this product could capture a substantial share of the human growth hormone market, providing a recurring revenue stream for OPKO. The timeline for commercialization depends on regulatory approvals and manufacturing capabilities.
• Development of OPK88003 for Type 2 Diabetes and Obesity: OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity, is currently in Phase IIb trials. If successful, this drug could address a large and growing market, as the prevalence of diabetes and obesity continues to rise globally. The timeline for potential commercialization depends on the outcome of clinical trials and regulatory approvals.
• Geographic Expansion: OPKO can expand its operations into new geographic markets, particularly in emerging economies where healthcare spending is increasing. This expansion could involve establishing new pharmaceutical platforms or partnering with local distributors to market its products. The timeline for geographic expansion depends on market research and regulatory approvals in each target country.
• Strategic Acquisitions: OPKO can pursue strategic acquisitions of companies with complementary technologies or products. This could include acquiring companies with novel diagnostic tests, pharmaceutical products, or drug delivery systems. Strategic acquisitions can accelerate OPKO's growth and diversify its revenue streams. The timeline for acquisitions depends on market conditions and the availability of suitable targets.

What Threats Does OPK Face?

• Regulatory changes and healthcare reforms.
• Competition from generic drugs.
• Product liability claims.
• Economic downturns affecting healthcare spending.

What Are OPK's Competitive Advantages?

• Proprietary diagnostic technologies, such as the 4Kscore prostate cancer testing service.
• Established relationships with healthcare providers and institutions through BioReference Laboratories.
• Portfolio of pharmaceutical products, including Rayaldee, with patent protection.
• Partnerships with major pharmaceutical companies, such as Pfizer, for the development and commercialization of therapeutic proteins.

What Does OPK Do?

Founded in 1991 and headquartered in Miami, Florida, OPKO Health, Inc. operates in the diagnostics and pharmaceuticals sectors across the United States, Ireland, Chile, Spain, Israel, and Mexico. The company's Diagnostics segment is anchored by BioReference Laboratories, which provides a comprehensive suite of laboratory testing services. These services encompass the detection, diagnosis, evaluation, monitoring, and treatment of various diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, and women's health. BioReference also serves correctional healthcare facilities, physician offices, clinics, hospitals, employers, and governmental units. OPKO's diagnostic offerings include a novel diagnostic instrument system for point-of-care blood test results and the 4Kscore prostate cancer testing service. The Pharmaceutical segment features Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency. OPKO is also developing OPK88004, an orally administered selective androgen receptor modulator, and OPK88003, a once-weekly administered peptide for type 2 diabetes and obesity, currently in Phase IIb trials. A key product in development is hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trials in partnership with Pfizer, Inc. OPKO develops and commercializes longer-acting proprietary versions of approved therapeutic proteins, along with specialty APIs, pharmaceutical, nutraceutical, veterinary, and ophthalmic products. The company also commercializes food supplements and over-the-counter products, manufactures generics, and imports, markets, distributes, and sells pharmaceutical products for cardiovascular, vaccine, antibiotic, gastro-intestinal, and hormone indications. OPKO operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico.

What Products and Services Does OPK Offer?

• Provides laboratory testing services through BioReference Laboratories.
• Develops and commercializes pharmaceutical products, including Rayaldee.
• Develops longer-acting proprietary versions of therapeutic proteins.
• Offers specialty APIs (Active Pharmaceutical Ingredients).
• Manufactures and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products.
• Commercializes food supplements and over-the-counter products.
• Imports, markets, distributes, and sells pharmaceutical products in various indications.

How Does OPK Make Money?

• Generates revenue from diagnostic testing services provided by BioReference Laboratories.
• Generates revenue from the sale of pharmaceutical products, including Rayaldee.
• Partners with other pharmaceutical companies for the development and commercialization of therapeutic proteins.
• Operates pharmaceutical platforms in international markets, including Ireland, Chile, Spain, and Mexico.

What Industry Does OPK Operate In?

OPKO Health operates within the healthcare industry, specifically in the medical diagnostics and research segment. This segment is characterized by continuous innovation, regulatory scrutiny, and evolving patient needs. The market for diagnostic testing services is growing, driven by increased awareness of preventive healthcare and advancements in molecular diagnostics. The pharmaceutical sector is highly competitive, with companies vying for market share through novel therapies and strategic partnerships. OPKO's focus on longer-acting therapeutic proteins and specialty APIs positions it within a niche market, potentially offering a competitive advantage.

Who Are OPK's Key Customers?

• Physician offices and clinics
• Governmental units
• Correctional healthcare facilities

Company Profile

OPKO Health, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Miami, US. The company is led by CEO Phillip Frost. OPK has traded publicly since 1995.

OPKO Health, Inc. Financial Trajectory

OPKO Health, Inc. (OPK) reported $163.6M in revenue for Q2 FY2026, reflecting 31.7% growth compared to the prior quarter. The company recorded a net loss of $8.4M, with diluted EPS of $-0.01. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, OPK averaged $-0.02 in diluted EPS.

How OPKO Health, Inc. Is Valued

OPKO Health, Inc. carries a market capitalization of $1.17B, placing it in the small-cap category. Analyst price targets span from $1.60 to $4.00, with a consensus of $2.87. At the current price of $1.57, that implies approximately 83% upside potential. Relative to its peer group, OPK's quantitative score of 18/100 is below the peer average of 51/100.

Return on equity for OPKO Health, Inc. stands at -16.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -11.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -15.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.61 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -18.4%, the inverse of the P/E and a quick read on earnings relative to price.

OPKO Health, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.29 places it in the distress zone, a signal of elevated financial risk.

OPKO Health, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 62.2% above estimates on average.

Over the past six months, OPKO Health, Inc. insiders filed 10 SEC Form 4 transactions — 2 sales and 8 purchases. On net that is roughly 213K shares acquired (about $309K) — insiders putting money in tends to read as conviction.

OPK Financials

OPK Latest News

OPK Analyst Consensus

OPK MoonshotScore

OPK Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources